Serum PSA and PAP measurements discriminating patients with prostate carcinoma from patients with nodular hyperplasia.
Prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) are the tumor markers for monitoring disease progression or improvement in patients with prostate adenocarcinoma. The clinical utility of PSA and PAP for early detection of prostate adenocarcinoma, however, requires distinction between prostate adenocarcinoma and prostate nodular hyperplasia. The serum PSA and PAP levels were measured in 20 men with histologically proven prostate adenocarcinoma and 28 men with histologically proven prostate nodular hyperplasia. Patients' blood samples were collected 1 to 7 days prior to the prostate examination, which included a rectal digital examination, transurethral resection, cytoscopy, and prostate biopsy. Sensitivity, specificity, and predictive values of positive and negative results for the discrimination of prostate adenocarcinoma from prostate nodular hyperplasia were 85%, 89%, 85%, and 29%, respectively, for serum PSA (cutoff level: 10 ng/mL) and 40%, 96%, 89%, and 69%, respectively, for serum PAP (cutoff level: 10 ng/mL). Results indicate that marked elevation of serum PSA suggests prostate adenocarcinoma and that serum PSA can discriminate prostate adenocarcinoma from prostate nodular hyperplasia better than serum PAP.
Shih
W J
WJ
Department of Veterans Affairs Medical Center, Lexington, Kentucky 40511.
Collins
J
J
Mitchell
B
B
Wierzbinski
B
B
D000135:Acid Phosphatase / Q000097:blood*; D000230:Adenocarcinoma / Q000097:blood*; D000328:Adult; D000368:Aged; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood*; D012680:Sensitivity and Specificity
D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen